Events

Critical Issues America2026 Annual Conference - February 6-7, 2026We invite you to attend our annual CRITICAL ISSUES america (CIA) meeting. The meeting will help participants to identify and manage complications associated with endovascular and open repair of complex aortic disease including: arch descending thoracic, TAAA, pararenal and juxtarenal aneurysms, aortoiliac aneurysms and other miscellaneous pathologies affecting the aorta. CIA will recognize potential treatment failure and the role of advance imaging techniques in the evaluation, treatment, and management of aortic disease. The target audience includes physicians who specialize in vascular surgery, cardiology, interventional radiology, vascular medicine, cardiothoracic surgery, as well as fellows, and allied health professiona…

Innovating Novel Combination Therapies and Maximising Preclinical and Clinical Development to Improve Glioblastoma Targeting and Increase Investment Opportunities to Ultimately Bring Efficacious Therapies to Patients in NeedThe glioblastoma drug development space has been energized by Merck's acquisition of Modifi Bio last December. This landmark deal has sparked renewed hope in a field long challenged by limited investment and clinical breakthroughs. Looking ahead to 2026, it's crucial to sustain this momentum. The 7th Glioblastoma Drug Development Summit is your essential platform for accelerating new treatments and continuing this vital progress. Join us for a definitive, 3-day summit designed to accelerate progress. With groundbreaking content and six deep-dive workshops, you'll connec…

In this two day workshop conference you will learn the requirements and expectations of major health care regulators that are applicable to "virtual" companies. You will learn how to diagnose your company's needs based on which GMP and GCP-governed operations you retain and which you outsource; what the current expectations and best industry practices are for selecting, qualifying and monitoring your contractors to ensure they are meeting your requirements; and how to build a quality system framework that is not excessive for your current needs, but has the structure and integration to "grow with you" as the scope your operations change in the coming months and years. Learning Objectives: Participants in this seminar will: Understand the GMP and GCP requirements all virtual companies must…

Use coupon COMPLIANCE15 to get 15% discount on this virtual seminar This seminar bridges that gap. Designed specifically for non-statisticians, it provides a clear, practical introduction to biostatistics without overwhelming you with mathematics. You’ll learn the “why” behind the numbers, gain tools to spot meaningful findings, and avoid being misled by misused statistics. By the end of the program, you’ll be able to read statistical reports with confidence, communicate findings to colleagues and stakeholders, and make better data-driven decisions that can shape the future of clinical and biotech innovation. Why Should You Attend: In the world of clinical research and biotechnology, numbers carry weight. A single statistical finding can influence whether a project moves forward, a regulat…

Use coupon COMPLIANCE15 to get 15% discount on this virtual seminar Sterile products may be broadly classified into two main categories based on their production mode -- those that are terminally sterilized following the filling and sealing of the container and those that are aseptically sterilized, that is, filter sterilized as a bulk product, filled, and then sealed. Aseptic Processing play a critical role with large molecules that cannot be terminally sterilized. The verification of the process to produce sterile product is evaluated through the demonstration of various media fill process simulations that will vary in both numbers and size of the containers as well as the volumes filled over a defined period.  Aseptic Processing involves risk assessment on an on-going basis because…

The 20th Clinical Research Billing Compliance Summit brings together compliance officers, billing specialists, and research leaders to share strategies, updates, and best practices for accurate, audit-ready billing. Learn from experts, join workshops, and network with peers February 23-25, 2026 in New Orleans. Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Clinical Date and Time: 23rd February 2026 at 9:00 am to 25th February 2026 at 5:00 pm Venue details: New Orleans Marriott Warehouse Arts District, 859 Convention Center Boulevard, New Orleans, Louisiana, 70130, United States

About NEURO 2026 We are delighted to welcome you to the 4th European Congress of Neurology and Neuropsychiatry (Earn CME/CPD Credits) which will take place on February 23-24, 2026 in Paris, France. Neurology Conference 2026 will bring together leading neurologists, neuropsychiatrists, researchers, and healthcare professionals from around the globe to discuss the latest developments in neurology, psychiatry, and brain health.   Building upon the resounding success of the 2nd European Congress held in London, UK and 3rd European Congress held in Amsterdam, Netherlands we are eager to continue the tradition of fostering collaboration, knowledge exchange, and innovation in the field of neurology and neuropsychiatry. Amsterdam, with its rich history, cult…

This program combines general considerations for Good Manufacturing Practice (GMP) compliance management with the principles of phase-appropriate GMP considerations, with an emphasis on needs of virtual companies. (“Virtual companies” are those who outsource GMP operations to Contract Manufacturing Organizations (CMOs) and Contract Analytical Laboratories.) Virtual companies typically do not conduct “hands on” manufacturing, but do perform tasks which are governed by GMP, for example, dispositioning final product, managing the supply chain, investigating complaints, and providing training to staff in GMP compliance concepts. Such companies often struggle to decide how to structure their quality management system, which procedures they need or do not need, and how to best manage vendor rela…

Uniting 100+ leaders from cutting-edge biotechs to global pharma, this summit delivers comprehensive insight across antigen selection, biomarker strategy, B-cell and cellular tolerance mechanisms, delivery platforms, and clinical trial execution. The 2026 agenda spotlights late-stage data from Topas, Diamyd, and COUR; novel mRNA- LNP approaches from Moderna; integrated nanotherapeutics; and next-generation Treg and tolerance-restoring strategies. Key sessions explore central versus peripheral tolerance, and how gene and cell therapy are redefining therapeutic durability and safety. Now in its ninth year, the 9th Antigen-Specific Immune Tolerance Summit remains the only end-to-end meeting dedicated to advancing antigen-specific immune tolerance. Join Pfizer, Moderna, AbbVie, Diamyd, COUR, a…

Event Overview Discover the breakthroughs shaping the future of medicine at this two-day event designed for scientists, innovators, and industry leaders. Our programme combines cutting-edge talks, interactive panel discussions, and dedicated networking opportunities to foster collaboration and spark new ideas: Gene Therapies for Neurological & Neurometabolic Disorders: Explore the full translational journey – from preclinical innovation to clinical trials – featuring a unique perspective from a parent whose child received gene therapy. Making New Medicines for Sensory Disorders: Learn how advanced modalities are transforming treatment for vision loss, hearing impairment, and neuropathic pain, and tackle the challenges of adoption and reimbursement. Individually Rare but Collectively C…

SAE Media Group's AI in Drug Discovery 2026 takes place 9–10 March in London. Join pharma and biotech leaders to explore how AI, ML, and generative tools are transforming drug pipelines. The agenda features case studies, clinical updates, and expert panels on target ID, computational design, and scaling AI across R and D. Discover the latest breakthroughs and connect with directors and heads of informatics, molecular design, and data science.   Date and Time: On Monday March 09, 2026 at 8:30 am to Tuesday March 10, 2026 at 6:00 pm Venue details: Hilton London Kensington, 179-199 Holland Park Avenue, London, England, W11 4UL, United Kingdom

The 6th TPD and Induced Proximity Summit Europe is the only European forum dedicated exclusively to proximity-based drug discovery. From PROTACs and molecular glues to stabilizers and extracellular degraders, this summit showcases the full spectrum of therapeutic innovation across oncology, neurodegeneration, immunology, and rare diseases. Held in London in March 2026, the event brings together more than 80 CxOs, directors, senior scientists and investors to accelerate proximity therapeutics from discovery to clinic. Europe is experiencing a surge in strategic investment and innovation, including Sanofi’s acquisition of Blueprint Medicines for £7.2 billion and Merck’s £2.7 billion purchase of SpringWorks Therapeutics. As the region pivots toward non-oncology indications and novel mechanism…

Dear Colleagues It is our pleasure to welcome you to the 19th International Conference on Advanced Technologies and Treatments (ATTD 2026) taking place at the fascinating city of Barcelona, on March 11-14, 2026. Join us at ATTD 2026, the premier international platform where a diverse community - clinicians, diabetes care providers, researchers, industry, startups, investors, reimbursement authorities, and regulators - collaborates to drive rapid progress in diabetes care. The conference program features presentations and discussions led by distinguished professionals, covering a wide spectrum of innovations from artificial intelligence and glucose technology to novel therapies and prevention strategies. We look forward to your contributions and active participation, which will be instrumen…

The Marcus Evans 16th Edition R&D Controlling and Performance Management conference taking place in Amsterdam, Netherlands on 16-18 March, 2026 will tackle into some of the toughest challenges R&D controllers face today: securing funding for projects with uncertain outcomes, making the intangible value of innovation visible, and balancing transparency with the freedom researchers need to create. This conference will guide you through practical tools and real scenarios to transform uncertainty into actionable choices. You’ll learn how to build flexible budgets that withstand change, translate innovation into business value executives can back, and confidently sell R&D as a strategic growth driver.  Attending this premier Marcus Evans conference will enable you to:• Win the…

Healthcare is changing faster than we can reactCompanies have had to make billion-dollar bets on AI, manufacturing, organizational models and CRM systems, going against decades of waiting for clarity before committing. But clarity isn't coming, and patients can't wait. Nor can we. It's time to stop predicting the future and prepare for all futures. What works across all of them? Patient-centricity and cross-functionality. Cross-functionality unlocks trapped capabilities. Functional excellence without structural integration fails in today's efficiency-first world. When Medical and Commercial align, omnichannel delivers and launches accelerate. Coordination that consumed months compresses into days. World-class skills finally operate at world-class velocity, built on the technology stacks an…

Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs, as well as the exploration of non-oncology indications. The 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored, what benefit each approach has and the directions the space is heading. Attendees gain valuable competitive insight into emerging technologies, early data, and the rationale behind each approach, from establishe…

The Annual Pharma Supply Chain & Security World Summit is back in London for the 8th time, and this time with more focus on optimising your supply chain challenges to ensure an agile, responsive, streamlined and secured supply chain. The pharmaceutical supply chains are facing a significant challenge in the form of counterfeit drugs that are entering the supply chain from various points at different levels. Pharmaceutical companies that adopt an effective serialisation program have end-to-end visibility and traceability for all of their packaging, labelling, and distribution. This enables them to rapidly identify and quarantine counterfeit products. This helps to protect patients, consumers worldwide, brand equity, reputations and the company's revenue stream by ensuring compliance…

The 2026 Annual Meeting of the American and Global College of Endometriosis Specialists (AGCES) will take place from 19–21 March 2026 in Las Vegas, Nevada, USA, under the theme "Pioneering the Future: AI and Innovation in Endometriosis and Adenomyosis Care." AGCES 2026 is an international scientific meeting focused on advancing clinical practice, research, and multidisciplinary management in endometriosis and adenomyosis. The program includes plenary lectures, symposia, panel discussions, case-based sessions, and surgical education addressing diagnostic strategies, surgical management, clinical outcomes, and emerging digital and data-driven approaches. The meeting is intended for clinicians, surgeons, researchers, and allied healthcare professionals and supports academic exchange. Patients…

Want to hear what sector’s most influential thinkers say about where AI and next-gen therapies are heading in 2026? AI is rapidly reshaping emerging biotech, advanced therapies and biologics in the UK. Machine learning now enables the analysis of large and complex datasets, supporting the discovery of new biomarkers and therapeutic targets and improving the modelling of biological responses. This leads to more precise and better targeted biologics and advanced therapies. UK biotech organisations are also forming deeper partnerships with technology companies to access advanced data analytics and embed AI more effectively into research pipelines. Government backed initiatives are strengthening this progress and accelerating innovation. AI driven drug repurposing is gaining momentum, helping…